{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:49:06Z","timestamp":1764175746608,"version":"3.32.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,20]]},"DOI":"10.7759\/cureus.76065","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T12:46:33Z","timestamp":1734698793000},"source":"Crossref","is-referenced-by-count":1,"title":["Safety and Efficacy of Ferric Carboxymaltose for Iron Deficiency Anemia in Inflammatory Bowel Disease: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Aparna","family":"Malireddi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahlet","family":"Abera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suchith B","family":"Suresh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehwish","family":"Ansar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sruthi","family":"Boddeti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khutaija","family":"Noor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safeera","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"The epidemiology and risk factors of inflammatory bowel disease","volume":"8","author":"Ye Y","year":"2015","unstructured":"Ye Y, Pang Z, Chen W, Ju S, Zhou C. The epidemiology and risk factors of inflammatory bowel disease. Int J Clin Exp Med. 2015, 8:22529-42.","journal-title":"Int J Clin Exp Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jju009","article-title":"European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases","volume":"9","author":"Dignass AU","year":"2015","unstructured":"Dignass AU, Gasche C, Bettenworth D, et al.. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015, 9:211-22. 10.1093\/ecco-jcc\/jju009","journal-title":"J Crohns Colitis"},{"key":"ref3","unstructured":"Nutritional Anaemias. Tools for effective prevention and control. (2017). https:\/\/www.who.int\/publications\/i\/item\/9789241513067."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab073","article-title":"Long-term effectiveness of oral ferric maltol vs intravenous ferric carboxymaltose for the treatment of iron-deficiency anemia in patients with inflammatory bowel disease: A randomized controlled noninferiority trial","volume":"28","author":"Howaldt S","year":"2022","unstructured":"Howaldt S, Dom\u00e8nech E, Martinez N, Schmidt C, Bokemeyer B. Long-term effectiveness of oral ferric maltol vs intravenous ferric carboxymaltose for the treatment of iron-deficiency anemia in patients with inflammatory bowel disease: A randomized controlled noninferiority trial. Inflamm Bowel Dis. 2022, 28:373-84. 10.1093\/ibd\/izab073","journal-title":"Inflamm Bowel Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2010.151","article-title":"Diagnosis and management of iron deficiency anemia in patients with IBD","volume":"7","author":"Stein J","year":"2010","unstructured":"Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol. 2010, 7:599-610. 10.1038\/nrgastro.2010.151","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy042","article-title":"Safety and efficacy of ferric carboxymaltose in the treatment of iron deficiency anaemia in patients with inflammatory bowel disease, in routine daily practice","volume":"12","author":"Stein J","year":"2018","unstructured":"Stein J, Aksan A, Klemm W, Nip K, Weber-Mangal S, Dignass A. Safety and efficacy of ferric carboxymaltose in the treatment of iron deficiency anaemia in patients with inflammatory bowel disease, in routine daily practice. J Crohns Colitis. 2018, 12:826-34. 10.1093\/ecco-jcc\/jjy042","journal-title":"J Crohns Colitis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/nu10010082","article-title":"Rational management of iron-deficiency anaemia in inflammatory bowel disease","volume":"10","author":"Nielsen OH","year":"2018","unstructured":"Nielsen OH, Soendergaard C, Vikner ME, Weiss G. Rational management of iron-deficiency anaemia in inflammatory bowel disease. Nutrients. 2018, 10:82. 10.3390\/nu10010082","journal-title":"Nutrients"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S284959","article-title":"An economic analysis of ferric derisomaltose versus ferric carboxymaltose in the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Norway, Sweden, and Finland","volume":"13","author":"Pollock RF","year":"2021","unstructured":"Pollock RF, Muduma G. An economic analysis of ferric derisomaltose versus ferric carboxymaltose in the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Norway, Sweden, and Finland. Clinicoecon Outcomes Res. 2021, 13:9-18. 10.2147\/CEOR.S284959","journal-title":"Clinicoecon Outcomes Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-016-0334-5","article-title":"Randomized open-label phase 1 study of the pharmacokinetics of ferric maltol in inflammatory bowel disease patients with iron deficiency","volume":"42","author":"Bokemeyer B","year":"2017","unstructured":"Bokemeyer B, Krummenerl A, Maaser C, Howaldt S, Mro\u00df M, Mallard N. Randomized open-label phase 1 study of the pharmacokinetics of ferric maltol in inflammatory bowel disease patients with iron deficiency. Eur J Drug Metab Pharmacokinet. 2017, 42:229-38. 10.1007\/s13318-016-0334-5","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics3010012","article-title":"The pharmacokinetics and pharmacodynamics of iron preparations","volume":"3","author":"Geisser P","year":"2011","unstructured":"Geisser P, Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics. 2011, 3:12-33. 10.3390\/pharmaceutics3010012","journal-title":"Pharmaceutics"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.61622\/rbgo\/2024AO21","article-title":"A meta-analysis of ferric carboxymaltose versus other intravenous iron preparations for the management of iron deficiency anemia during pregnancy","volume":"46","author":"Gupte S","year":"2024","unstructured":"Gupte S, Mukhopadhyay A, Puri M, Gopinath PM, Wani R, Sharma JB, Swami OC. A meta-analysis of ferric carboxymaltose versus other intravenous iron preparations for the management of iron deficiency anemia during pregnancy. Rev Bras Ginecol Obstet. 2024, 46:10.61622\/rbgo\/2024AO21","journal-title":"Rev Bras Ginecol Obstet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v11.i12.2740","article-title":"Ferric carboxymaltose for anemia in Crohn's disease patients at a tertiary center: a retrospective observational cohort study","volume":"11","author":"Siqueira NS","year":"2023","unstructured":"Siqueira NS, Pascoal LB, Rodrigues BL, et al.. Ferric carboxymaltose for anemia in Crohn's disease patients at a tertiary center: a retrospective observational cohort study. World J Clin Cases. 2023, 11:2740-52. 10.12998\/wjcc.v11.i12.2740","journal-title":"World J Clin Cases"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01744.x","article-title":"A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial","volume":"103","author":"Kulnigg S","year":"2008","unstructured":"Kulnigg S, Stoinov S, Simanenkov V, et al.. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol. 2008, 103:1182-92. 10.1111\/j.1572-0241.2007.01744.x","journal-title":"Am J Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14043","article-title":"Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease","volume":"45","author":"Aksan A","year":"2017","unstructured":"Aksan A, I\u015f\u0131k H, Radeke HH, Dignass A, Stein J. Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017, 45:1303-18. 10.1111\/apt.14043","journal-title":"Aliment Pharmacol Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2013.819442","article-title":"Anemia and iron deficiency in inflammatory bowel disease: an open, prospective, observational study on diagnosis, treatment with ferric carboxymaltose and quality of life","volume":"48","author":"Befrits R","year":"2013","unstructured":"Befrits R, Wikman O, Blomquist L, et al.. Anemia and iron deficiency in inflammatory bowel disease: an open, prospective, observational study on diagnosis, treatment with ferric carboxymaltose and quality of life. Scand J Gastroenterol. 2013, 48:1027-32. 10.3109\/00365521.2013.819442","journal-title":"Scand J Gastroenterol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2450\/2016.0246-15","article-title":"High-dose intravenous treatment in iron deficiency anaemia in inflammatory bowel disease: early efficacy and impact on quality of life","volume":"14","author":"Garc\u00eda-L\u00f3pez S","year":"2016","unstructured":"Garc\u00eda-L\u00f3pez S, Bocos JM, Gisbert JP, et al.. High-dose intravenous treatment in iron deficiency anaemia in inflammatory bowel disease: early efficacy and impact on quality of life. Blood Transfus. 2016, 14:199-205. 10.2450\/2016.0246-15","journal-title":"Blood Transfus"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2018.1441435","article-title":"Inflammatory bowel disease and anemia: intravenous iron treatment","volume":"53","author":"Kangaspunta M","year":"2018","unstructured":"Kangaspunta M, Haapam\u00e4ki J, F\u00e4rkkil\u00e4 M, Arkkila P. Inflammatory bowel disease and anemia: intravenous iron treatment. Scand J Gastroenterol. 2018, 53:430-4. 10.1080\/00365521.2018.1441435","journal-title":"Scand J Gastroenterol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1159\/000333091","article-title":"Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease","volume":"85","author":"Beigel F","year":"2012","unstructured":"Beigel F, L\u00f6hr B, Laubender RP, et al.. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease. Digestion. 2012, 85:47-54. 10.1159\/000333091","journal-title":"Digestion"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128156","article-title":"Safety of ferric carboxymaltose immediately after infliximab administration, in a single session, in inflammatory bowel disease patients with iron deficiency: a pilot study","volume":"10","author":"Cortes X","year":"2015","unstructured":"Cortes X, Borr\u00e1s-Blasco J, Mol\u00e9s JR, Bosc\u00e1 M, Cort\u00e9s E. Safety of ferric carboxymaltose immediately after infliximab administration, in a single session, in inflammatory bowel disease patients with iron deficiency: a pilot study. PLoS One. 2015, 10:e0128156. 10.1371\/journal.pone.0128156","journal-title":"PLoS One"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-28032015000400002","article-title":"Treatment of anemia and improvement of quality of life among patients with Crohn\u2019s disease: experience using ferric carboxymaltose","volume":"52","author":"Sobrado CW","year":"2015","unstructured":"Sobrado CW, Can\u00e7ado RD, Sobrado LF, Frugis MO, Sobrado MF. Treatment of anemia and improvement of quality of life among patients with Crohn\u2019s disease: experience using ferric carboxymaltose. Arq Gastroenterol. 2015, 52:255-9. 10.1590\/S0004-28032015000400002","journal-title":"Arq Gastroenterol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i17.2039","article-title":"Hypophosphatemia after high-dose intravenous iron treatment in patients with inflammatory bowel disease: Mechanisms and possible clinical impact","volume":"27","author":"Detlie TE","year":"2021","unstructured":"Detlie TE, Lindstr\u00f8m JC, Jahnsen ME, Finnes E, Zoller H, Moum B, Jahnsen J. Hypophosphatemia after high-dose intravenous iron treatment in patients with inflammatory bowel disease: Mechanisms and possible clinical impact. World J Gastroenterol. 2021, 27:2039-53. 10.3748\/wjg.v27.i17.2039","journal-title":"World J Gastroenterol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.06.005","article-title":"FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease","volume":"141","author":"Evstatiev R","year":"2011","unstructured":"Evstatiev R, Marteau P, Iqbal T, et al.. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011, 141:846-853.e1-2. 10.1053\/j.gastro.2011.06.005","journal-title":"Gastroenterology"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.10.013","article-title":"Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease","volume":"11","author":"Evstatiev R","year":"2013","unstructured":"Evstatiev R, Alexeeva O, Bokemeyer B, et al.. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013, 11:269-77. 10.1016\/j.cgh.2012.10.013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/nu13020608","article-title":"Oral sucrosomial iron is as effective as intravenous ferric carboxy-maltose in treating anemia in patients with ulcerative colitis","volume":"13","author":"Bertani L","year":"2021","unstructured":"Bertani L, Tric\u00f2 D, Zanzi F, et al.. Oral sucrosomial iron is as effective as intravenous ferric carboxy-maltose in treating anemia in patients with ulcerative colitis. Nutrients. 2021, 13:608. 10.3390\/nu13020608","journal-title":"Nutrients"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327897","article-title":"Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial","volume":"72","author":"Zoller H","year":"2023","unstructured":"Zoller H, Wolf M, Blumenstein I, et al.. Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial. Gut. 2023, 72:644-53. 10.1136\/gutjnl-2022-327897","journal-title":"Gut"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2003.12.011","article-title":"Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature","volume":"116 Suppl 7A","author":"Wilson A","year":"2004","unstructured":"Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med. 2004, 116 Suppl 7A:44S-9S. 10.1016\/j.amjmed.2003.12.011","journal-title":"Am J Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.4659","article-title":"Anemia and inflammatory bowel diseases","volume":"15","author":"Gomoll\u00f3n F","year":"2009","unstructured":"Gomoll\u00f3n F, Gisbert JP. Anemia and inflammatory bowel diseases. World J Gastroenterol. 2009, 15:4659-65. 10.3748\/wjg.15.4659","journal-title":"World J Gastroenterol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2011.09.010","article-title":"Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis","volume":"6","author":"Lee TW","year":"2012","unstructured":"Lee TW, Kolber MR, Fedorak RN, van Zanten SV. Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis. J Crohns Colitis. 2012, 6:267-75. 10.1016\/j.crohns.2011.09.010","journal-title":"J Crohns Colitis"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.02.009","article-title":"The microbiome in inflammatory bowel disease: current status and the future ahead","volume":"146","author":"Kostic AD","year":"2014","unstructured":"Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014, 146:1489-99. 10.1053\/j.gastro.2014.02.009","journal-title":"Gastroenterology"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000963","article-title":"Management of iron-deficiency anemia in inflammatory bowel disease: a systematic review","volume":"94","author":"Nielsen OH","year":"2015","unstructured":"Nielsen OH, Ainsworth M, Coskun M, Weiss G. Management of iron-deficiency anemia in inflammatory bowel disease: a systematic review. Medicine (Baltimore). 2015, 94:e963. 10.1097\/MD.0000000000000963","journal-title":"Medicine (Baltimore)"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002308","article-title":"Intravenous versus oral iron for the treatment of anemia in inflammatory bowel disease: a systematic review and meta-analysis of randomized controlled trials","volume":"95","author":"Bonovas S","year":"2016","unstructured":"Bonovas S, Fiorino G, Allocca M, Lytras T, Tsantes A, Peyrin-Biroulet L, Danese S. Intravenous versus oral iron for the treatment of anemia in inflammatory bowel disease: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016, 95:e2308. 10.1097\/MD.0000000000002308","journal-title":"Medicine (Baltimore)"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075540","article-title":"Treatment of anemia in inflammatory bowel disease--systematic review and meta-analysis","volume":"8","author":"Avni T","year":"2013","unstructured":"Avni T, Bieber A, Steinmetz T, Leibovici L, Gafter-Gvili A. Treatment of anemia in inflammatory bowel disease--systematic review and meta-analysis. PLoS One. 2013, 8:e75540. 10.1371\/journal.pone.0075540","journal-title":"PLoS One"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1097\/01.mib.0000235097.86360.04","article-title":"Impaired intestinal iron absorption in Crohn's disease correlates with disease activity and markers of inflammation","volume":"12","author":"Semrin G","year":"2006","unstructured":"Semrin G, Fishman DS, Bousvaros A, et al.. Impaired intestinal iron absorption in Crohn's disease correlates with disease activity and markers of inflammation. Inflamm Bowel Dis. 2006, 12:1101-6. 10.1097\/01.mib.0000235097.86360.04","journal-title":"Inflamm Bowel Dis"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.009985","article-title":"Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment","volume":"95","author":"Bergamaschi G","year":"2010","unstructured":"Bergamaschi G, Di Sabatino A, Albertini R, et al.. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment. Haematologica. 2010, 95:199-205. 10.3324\/haematol.2009.009985","journal-title":"Haematologica"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200969060-00007","article-title":"Ferric carboxymaltose: a review of its use in iron-deficiency anaemia","volume":"69","author":"Lyseng-Williamson KA","year":"2009","unstructured":"Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs. 2009, 69:739-56. 10.2165\/00003495-200969060-00007","journal-title":"Drugs"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124486","article-title":"Randomized trial of intravenous iron-induced hypophosphatemia","volume":"3","author":"Wolf M","year":"2018","unstructured":"Wolf M, Chertow GM, Macdougall IC, Kaper R, Krop J, Strauss W. Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight. 2018, 3:10.1172\/jci.insight.124486","journal-title":"JCI Insight"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-019-0189-5","article-title":"FGF23 at the crossroads of phosphate, iron economy and erythropoiesis","volume":"16","author":"Edmonston D","year":"2020","unstructured":"Edmonston D, Wolf M. FGF23 at the crossroads of phosphate, iron economy and erythropoiesis. Nat Rev Nephrol. 2020, 16:7-19. 10.1038\/s41581-019-0189-5","journal-title":"Nat Rev Nephrol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.218","article-title":"Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism","volume":"8","author":"Quarles LD","year":"2012","unstructured":"Quarles LD. Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat Rev Endocrinol. 2012, 8:276-86. 10.1038\/nrendo.2011.218","journal-title":"Nat Rev Endocrinol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1007\/BF01496662","article-title":"Hypophosphatemia induced by intravenous administration of Saccharated iron oxide","volume":"61","author":"Okada M","year":"1983","unstructured":"Okada M, Imamura K, Iida M, Fuchigami T, Omae T. Hypophosphatemia induced by intravenous administration of Saccharated iron oxide. Klin Wochenschr. 1983, 61:99-102. 10.1007\/BF01496662","journal-title":"Klin Wochenschr"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000329","article-title":"Iron-induced hypophosphatemia: an emerging complication","volume":"26","author":"Zoller H","year":"2017","unstructured":"Zoller H, Schaefer B, Glodny B. Iron-induced hypophosphatemia: an emerging complication. Curr Opin Nephrol Hypertens. 2017, 26:266-75. 10.1097\/MNH.0000000000000329","journal-title":"Curr Opin Nephrol Hypertens"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/305564-safety-and-efficacy-of-ferric-carboxymaltose-for-iron-deficiency-anemia-in-inflammatory-bowel-disease-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T12:46:37Z","timestamp":1734698797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/305564-safety-and-efficacy-of-ferric-carboxymaltose-for-iron-deficiency-anemia-in-inflammatory-bowel-disease-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":41,"URL":"https:\/\/doi.org\/10.7759\/cureus.76065","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,20]]}}}